Suchergebnisse - "Agostinetto, Elisa"

PubPharm (68)

1

The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab : An Exploratory Analysis of the CLEOPATRA Trial

enthalten in: Clinical breast cancer | 2024

von Debien, V. | Agostinetto, E. | Bruzzone, M. | +7

2

Adjuvant CDK4/6 Inhibitors for Early Breast Cancer : How to Choose Wisely?

enthalten in: Oncology and therapy | 2024

von Agostinetto, E. | Arecco, L. | de Azambuja, E.

3

Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer : A systematic review and meta-analysis

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Jacobs, F. | Molinelli, C. | Martins-Branco, D. | +7

4

Pregnancy After Breast Cancer in Young BRCA Carriers : An International Hospital-Based Cohort Study

enthalten in: JAMA | 2024

von Lambertini, M. | Blondeaux, E. | Agostinetto, E. | +152

CommentIn: JAMA. 2024 Apr 9;331(14):1233-1234. - PMID 38592393

5

Author Correction : Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

enthalten in: Nature communications | 2023

von Buisseret, L. | Loirat, D. | Aftimos, P. | +33

ErratumFor: Nat Commun. 2023 Nov 2;14(1):7018. - PMID 37919269

6

First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer : results of the safety run-in phase of the Neo-CheckRay trial

enthalten in: Journal for immunotherapy of cancer | 2023

von De Caluwe, A. | Romano, E. | Poortmans, P. | +18

7

Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?

enthalten in: Rare Cancers and Therapy | 2023

von Agostinetto, E. | Arecco, L. | de Azambuja, E.

8

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer : the randomized SYNERGY phase I/II trial

enthalten in: Nature communications | 2023

von Buisseret, L. | Loirat, D. | Aftimos, P. | +33

ErratumIn: Nat Commun. 2023 Dec 12;14(1):8223. - PMID 38086864

9

Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab

enthalten in: Critical reviews in oncology/hematology | 2023

von Debien, V. | Marta, G. | Agostinetto, E. | +16

10

Circulating tumor DNA in breast cancer : a biomarker for patient selection

enthalten in: Current opinion in oncology | 2023

von Agostinetto, E. | Nader-Marta, G. | Ignatiadis, M.

1
2
3
4
5
6
7
Nächster »
[7]